IPA (ImmunoPrecise Antibodies) Interest Coverage : 0 (At Loss) (As of Jan. 2025)

ImmunoPrecise Antibodies Interest Coverage Chart

ImmunoPrecise Antibodies Annual Data
	Trend	Dec14	Dec15	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23	Apr24
Interest Coverage		Get a 7-Day Free Trial					-	-	-	-	-

ImmunoPrecise Antibodies Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Interest Coverage	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of ImmunoPrecise Antibodies's Interest Coverage

For the Biotechnology subindustry, ImmunoPrecise Antibodies's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmunoPrecise Antibodies's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoPrecise Antibodies's Interest Coverage distribution charts can be found below:

* The bar in red indicates where ImmunoPrecise Antibodies's Interest Coverage falls into.

ImmunoPrecise Antibodies Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Else if Interest Expense is negative and Operating Income is negative, then

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

ImmunoPrecise Antibodies's Interest Coverage for the fiscal year that ended in Apr. 2024 is calculated as

Here, for the fiscal year that ended in Apr. 2024, ImmunoPrecise Antibodies's Interest Expense was $-0.01 Mil. Its Operating Income was $-10.06 Mil. And its Long-Term Debt & Capital Lease Obligation was $8.86 Mil.

ImmunoPrecise Antibodies's Interest Coverage for the quarter that ended in Jan. 2025 is calculated as

Here, for the three months ended in Jan. 2025, ImmunoPrecise Antibodies's Interest Expense was $-0.12 Mil. Its Operating Income was $-2.29 Mil. And its Long-Term Debt & Capital Lease Obligation was $7.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

ImmunoPrecise Antibodies  (NAS:IPA) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

ImmunoPrecise Antibodies Interest Coverage Related Terms

Thank you for viewing the detailed overview of ImmunoPrecise Antibodies's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunoPrecise Antibodies Business Description